<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01932385</url>
  </required_header>
  <id_info>
    <org_study_id>QCH20130823</org_study_id>
    <nct_id>NCT01932385</nct_id>
  </id_info>
  <brief_title>Sorafenib in Liver Function Impaired Advanced Hepatocellular Carcinoma</brief_title>
  <official_title>Phase 2 Study of Sorafenib in the Management of Liver Function Impaired Advanced Hepatocellular Carcinoma</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Qingdao Central Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Qingdao Central Hospital</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Due to the HBV and HCV infection, about 55% hepatocellular carcinoma patients happened in
      China. Among them, only 10% patients can be diagnosed in early stage. Sorafenib increased PFS
      and OS in advanced hepatocellular carcinoma patients with liver function of Child-Pugh class
      A patients, but the result for Child-Pugh class B patients is unclear.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>August 1, 2013</start_date>
  <completion_date type="Actual">July 30, 2016</completion_date>
  <primary_completion_date type="Actual">January 30, 2016</primary_completion_date>
  <phase>Phase 2/Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>progression free survival and overall survival</measure>
    <time_frame>From date of randomization until the date of first documented progression or date of death from any cause up to 12 months</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>response rate</measure>
    <time_frame>every 4 weeks till progression, total up to 12 months</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">86</enrollment>
  <condition>Liver Cancer</condition>
  <arm_group>
    <arm_group_label>sorafenib</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>sorafenib 400mg, oral, twice a day until disease progression defined by RECIST.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Best Supportive Care</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>treatment mainly on nutrition and symptoms control</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Sorafenib</intervention_name>
    <arm_group_label>sorafenib</arm_group_label>
    <other_name>Nexavar</other_name>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Best Supportive Care</intervention_name>
    <arm_group_label>sorafenib</arm_group_label>
    <arm_group_label>Best Supportive Care</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  pathological or cytological confirmed advanced hepatocellular carcinoma

          -  18 years to 80 years

          -  liver function Child-Pugh class B

          -  BCLC stage B or C

          -  estimated life time 2 months or longer

        Exclusion Criteria:

          -  previous target therapy

          -  allergy to Sorafenib

          -  Uncontrolled Bleeding or diarrhea

          -  eligible for locoregional treatment
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>ketao lan, M.D.</last_name>
    <role>Study Director</role>
    <affiliation>Qingdao Health Bereau</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Qingdao Central Hospital, Qingdao Cancer Hospital</name>
      <address>
        <city>Qingdao</city>
        <state>Shandong</state>
        <zip>266042</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>October 2015</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>August 22, 2013</study_first_submitted>
  <study_first_submitted_qc>August 27, 2013</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 30, 2013</study_first_posted>
  <last_update_submitted>February 13, 2018</last_update_submitted>
  <last_update_submitted_qc>February 13, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">February 14, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Qingdao Central Hospital</investigator_affiliation>
    <investigator_full_name>Youxin Ji</investigator_full_name>
    <investigator_title>Chief, Department of Oncology</investigator_title>
  </responsible_party>
  <keyword>Sorafenib</keyword>
  <keyword>Hepatocellular carcinoma</keyword>
  <keyword>Best supportive care</keyword>
  <keyword>Survival</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Carcinoma</mesh_term>
    <mesh_term>Carcinoma, Hepatocellular</mesh_term>
    <mesh_term>Liver Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Sorafenib</mesh_term>
    <mesh_term>Niacinamide</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

